European journal of hospital pharmacy : science and practice最新文献

{"title":"Long-term stability of esketamine in polypropylene syringes at 5 ± 3°C.","authors":"Amélie Kinet-Poleur, Marie-Lise Colsoul, Emilie Catry, Benoît P Bihin, Barbara E Sneyers, Justine Hubert, Jacques Jamart, Laura Soumoy, Laurence M Galanti, Jean-Daniel Hecq, Mélanie Closset","doi":"10.1136/ejhpharm-2024-004227","DOIUrl":"10.1136/ejhpharm-2024-004227","url":null,"abstract":"<p><strong>Objective: </strong>Esketamine (Vesierra) is a molecule, used alone or in combination, to induce and maintain general anaesthesia and to relieve pain in emergency medicine. The aim of this study is to evaluate the long-term physicochemical stability of a 1 mg/mL solution of esketamine diluted in 0.9% sodium chloride (NaCl) and stored in polypropylene syringes at 5±3°C during 65 days (64+1 day at 22±3°C) and 72 hours at 22±3°C (room temperature), in order to centralise preparation under aseptic conditions in hospital pharmacy.</p><p><strong>Methods: </strong>Ten syringes were prepared under aseptic conditions. Five syringes were stored at 22±3°C for 3 days, and the five others were stored at 5±3°C for 64 days (+ 1 day at room temperature). The stability was periodically investigated. Particle appearance or colour changes were checked by visual inspection. A research of crystals was performed under the microscope. pH was followed to assess its stability. The turbidity of the solutions was estimated by a measure of optical densities at 350, 410 and 550 nm. The molecule concentrations were measured by ultra-high performance liquid chromatography (UHPLC) coupled with a photodiode array detection (PDA), using a newly developed method.</p><p><strong>Results: </strong>Based on microscopic examination, no crystals were observed, during the observation period. pH and absorbances at 350, 410 and 550 nm were also stable. Macroscopically, there was no change in colour and appearance of opacity, turbidity or precipitation. Statistical analysis indicates that 1 mg/mL esketamine solutions were chemically stable under these conditions, given that less than 5% of the solutions have lost more than 10% of their initial content during the study based on the prediction interval.</p><p><strong>Conclusions: </strong>One mg/mL solutions of esketamine hydrochloride are physically and chemically stable after production, for at least 72 hours at 22±3°C and 64 days at 5±3°C (+ 1 day at room temperature).</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"376-380"},"PeriodicalIF":1.6,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141859432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective study of patient characteristics and treatment for mucormycosis in post COVID-19 population in a tertiary care hospital.","authors":"Jada Naga Lakshmi, Jada Bala Sai Kalyan, Tanniru Govardhana Priya, Tummala Sushma, Gaddam Rukmini, R V L S Mounica, Tinnaluri Vishnu Vardhan","doi":"10.1136/ejhpharm-2024-004127","DOIUrl":"10.1136/ejhpharm-2024-004127","url":null,"abstract":"<p><strong>Objectives: </strong>Along with the COVID-19 pandemic, another illness wreaking havoc in India is mucormycosis, also known as black fungus. Mucormycosis was previously known as zygomycotic infection, which is a consequential type of infection caused by several mildews known as Mucoromycetes. It is an invasive type of disease which occurs more commonly in individuals with low and weakened immunity. The main objective of this study was to identify the mucormycosis cases post COVID-19 and to determine the risk factors and treatment for positive cases.</p><p><strong>Methods: </strong>Thirty-three patients (61% men, 39% women; mean age 55 years) with mucormycosis were identified in the Department of Oral and Maxillofacial Surgery.</p><p><strong>Results: </strong>People who received COVID-19 vaccines had a lower rate of infection with the fungus than non-vaccinated people. In steroid users the risk was very high compared with those not taking steroids.</p><p><strong>Conclusion: </strong>The majority of non vaccinated patients with preexisting co-morbidity conditions like diabetes, chronic illnesses and irregular use of steroids during COVID-19, might have greater risks of getting mucormycosis rather than normal COVID-19 positive cases.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"334-337"},"PeriodicalIF":1.6,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141317200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing health outcomes: a systematic review of electronic patient-reported outcomes in oncology.","authors":"Mikel Urretavizcaya, Karen Álvarez, Olatz Olariaga, Maria Jose Tames, Ainhoa Asensio, Gerardo Cajaraville, Ana Cristina Riestra","doi":"10.1136/ejhpharm-2023-004072","DOIUrl":"10.1136/ejhpharm-2023-004072","url":null,"abstract":"<p><strong>Purpose: </strong>This study investigates the clinical impact of electronic patient-reported outcome (ePRO) monitoring apps/web interfaces, aimed at symptom-management, in cancer patients undergoing outpatient systemic antineoplastic treatment. Additionally, it explores the advantages offered by these applications, including their functionalities and healthcare team-initiated follow-up programmes.</p><p><strong>Methods: </strong>A systematic literature review was conducted using a predefined search strategy in MEDLINE. Inclusion criteria encompassed primary studies assessing symptom burden through at-home ePRO surveys in adult cancer patients receiving outpatient systemic antineoplastic treatment, whenever health outcomes were evaluated. Exclusion criteria excluded telemedicine-based interventions other than ePRO questionnaires and non-primary articles or study protocols. To evaluate the potential bias in the included studies, an exhaustive quality assessment was conducted, as an additional inclusion filter.</p><p><strong>Results: </strong>Among 246 identified articles, 227 were excluded for non-compliance with inclusion/exclusion criteria. Of the remaining 19 articles, only eight met the rigorous validity assessment and were included for detailed examination and data extraction, presented in attached tables.</p><p><strong>Conclusion: </strong>This review provides compelling evidence of ePRO monitoring's positive clinical impact across diverse cancer settings, encompassing various cancer types, including early and metastatic stages. These systems are crucial in enabling timely interventions and reducing communication barriers, among other functionalities. While areas for future ePRO innovation are identified, the primary limitation lies in comparing clinical outcomes of reviewed articles, due to scale variability and study population heterogeneity. To conclude, our results reaffirm the transformative potential of ePRO apps in oncology and their pivotal role in shaping the future of cancer care.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"299-306"},"PeriodicalIF":1.6,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141183713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physicochemical and biological stability of diluted vedolizumab in intravenous infusion bags.","authors":"Tine C J Hendrickx, Kevin D H Balcaen, Marielle Baert, Jurgen Haustraete, Bart N Lambrecht","doi":"10.1136/ejhpharm-2023-003844","DOIUrl":"10.1136/ejhpharm-2023-003844","url":null,"abstract":"<p><strong>Introduction: </strong>Intravenous vedolizumab is a widely used monoclonal antibody for outpatients with inflammatory bowel disease. Drug preparation is performed on the day of administration, but is time consuming, causing unnecessary in-hospital patient delay and inefficient logistics for preparation and distribution. Storage of vedolizumab ready-to-administer infusions and distribution via pneumatic air tubes could streamline logistics in the outpatient setting. The aim of this study was to test the shelf life and stability of ready-to-administer intravenous infusion bags containing vedolizumab.</p><p><strong>Methods: </strong>For assessing in-use shelf life, the reconstituted product (300 mg fixed dose) was diluted to a concentration of 1.2 mg/mL in 0.9% NaCl under aseptic conditions, and stored in polyolefin infusion bags at 2-8°C prior to analysis. On replicate samples, we measured concentration, physical and chemical stability using sodium dodecyl sulphate polyacrylamide gel electrophoresis, size exclusion chromatography, and multi-angle laser light scattering, as well as biological activity using a biolayer interferometry assay to study target engagement, and endotoxin content to assess microbiological stability. Stability of ready-to-use vedolizumab was assessed also after transportation via pneumatic tube system. Samples were taken at different time points over an observation period of 30 days on four replicate samples.</p><p><strong>Results: </strong>For all parameters assessed, the ready-to-use solution of vedolizumab remained stable over a period of at least 30 days. There were no signs of protein aggregation, chemical instability, or loss of binding of the antibody to the α4β7 integrin target. There was no increase in endotoxin concentration over time. No significant difference was seen in antibody structural stability and protein aggregation between samples before and after transportation via pneumatic tube system.</p><p><strong>Conclusion: </strong>When prepared under aseptic conditions, dissolved ready-to-administer vedolizumab infusion bags can be stored long term at 2-8°C and transported via pneumatic air tube, without observable loss of antibody stability or binding activity.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"367-375"},"PeriodicalIF":1.6,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139424592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential medicine waste in the process of outpatients receiving cost-free medicines from medicine pick-up lockers in the North Denmark region.","authors":"Lisa Greve Routhe, Iben Bang Andersen, Mille Vraa Gamborg Eisenhardt, Maja Beck Mejlholm, Helena Birk Wisby, Anne Estrup Olesen","doi":"10.1136/ejhpharm-2024-004224","DOIUrl":"10.1136/ejhpharm-2024-004224","url":null,"abstract":"<p><strong>Objectives: </strong>In the Danish healthcare system, restructuring is an ongoing process to accommodate the rising number of patients and to optimise resource allocation. To ease departmental burdens at hospitals in the North Denmark Region, outpatients are empowered to collect their cost-free medicines from medication pick-up lockers. The lockers function similarly to a package box, thereby enhancing patient freedom. Due to lack of evidence within the published literature regarding cost-free medicines and medicine waste, the aim of our study was to identify the common medications delivered to medicine pick-up lockers and secondly, to evaluate potential medicine waste.</p><p><strong>Methods: </strong>Data from ApoVision provided insights into medications delivered to medicine pick-up lockers from March to October 2023 in the North Denmark Region. To estimate unused medicines we obtained data on the number of medications returned from medicine pick-up lockers.</p><p><strong>Results: </strong>From 2020 to 2023, the number of patients receiving cost-free medicines at medication pick-up lockers increased. In total, approximately 30 000 packages of medicine were delivered to medicine pick-up lockers from March to October 2023 in the North Denmark Region; 1.7% were returned. Methotrexate, adalimumab, and omalizumab were among the most common deliveries and were also the three most returned from the medicine pick-up lockers.</p><p><strong>Conclusions: </strong>This study is an initial attempt to investigate potential medicine waste in cost-free medicines dispensed to outpatients via pick-up lockers. Antineoplastic and immunomodulating agents were the most common medicines delivered to medication pick-up lockers in the North Denmark Region from March to October 2023. In this period, approximately 2% of all delivered medicine packages were returned to the hospital pharmacy. Our analysis solely focuses on waste associated with medications left uncollected from medicine pick-up lockers. Addressing the impact of medicine waste in a hospital setting requires a comprehensive approach, thus future studies should also focus on other sites relevant for medication waste as, for example, the patient's household.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"329-333"},"PeriodicalIF":1.6,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141456095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RETRACTION-Specific features of rational pharmacotherapy in elderly patients.","authors":"","doi":"10.1136/ejhpharm-2021-002980ret","DOIUrl":"10.1136/ejhpharm-2021-002980ret","url":null,"abstract":"","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"396"},"PeriodicalIF":1.6,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139706486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Broad perspective on the relationship between soticlestat and QT interval in patients with epilepsy.","authors":"Yusuf Ziya Şener, Alexandr Ceasovschih, Andrej Belančić","doi":"10.1136/ejhpharm-2024-004429","DOIUrl":"10.1136/ejhpharm-2024-004429","url":null,"abstract":"","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"395-396"},"PeriodicalIF":1.6,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142964203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nine years' experience of an educational programme for patients treated with oral anticoagulants in a cardiology department.","authors":"Elisabeth Leclerc, Pauline Cavagna, Anne-Claire Cuquel, Cécile Chung, Victoria Gauthier, Diane Lastennet, Christine Fernandez, Ernesto Brito, Ariel Cohen, Marie Antignac","doi":"10.1136/ejhpharm-2024-004372","DOIUrl":"https://doi.org/10.1136/ejhpharm-2024-004372","url":null,"abstract":"<p><strong>Objectives: </strong>Oral anticoagulants present significant risks of iatrogenic complications. An educational programme dedicated to patients treated with vitamin-K antagonists (VKAs) or direct oral anticoagulants (DOACs) was set up in our cardiology department in 2013. The aim of this study is to describe and assess our programme's effectiveness, through evaluation of patients' skills and adherence, and to identify associated factors.</p><p><strong>Methods: </strong>Skills were assessed through a questionnaire designed by our multidisciplinary team, targeting different items, and a global score was rated from 0 to 1. Adherence was assessed using a validated tool. Data from patients educated between January 2013 and December 2021 were collected retrospectively. R software was used for statistical analysis, performing Student or χ² tests for comparison of variables and univariate linear regression analysis for identification of variability factors. A value of p<0.05 was considered significant.</p><p><strong>Results: </strong>Since 2013, 934 patients were educated, representing 14.7% of patients with oral anticoagulants in cardiology units. Mean±SD age was 68.7±16.4 years and the proportion of men was 58.9%. After hospital discharge, skills were assessed for 334 patients: mean score was 0.80±0.17 (minimum 0.1 to maximum 1). Younger patients presented higher scores than older ones (p<0.001). Adherence was assessed for 331 patients: levels were high, medium and low for 58%, 31.4% and 10.6% of them, respectively. Women presented higher adherence than men (p=0.01). Neither oral anticoagulant type (VKA or DOAC) nor characteristics of educational sessions presented significant association with skills or adherence.</p><p><strong>Conclusions: </strong>Our programme educated a large number of patients and seems to fit with VKAs and DOACs. Improvement areas could be to increase patient assessment and to reinforce education of elderly patients.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of potential particulate contamination in intravenous solutions in an adult intensive care unit: a targeted correlation analysis.","authors":"Yvonne Remane, Annett Frisch, Johanna Krainz, Jan Vogel, Donald Ranft, Julia Borella, Vincent-Christoph Klaus, Sirak Petros, Thilo Bertsche","doi":"10.1136/ejhpharm-2025-004523","DOIUrl":"https://doi.org/10.1136/ejhpharm-2025-004523","url":null,"abstract":"<p><strong>Background: </strong>Intravenous drug administration is essential in intensive care treatment. However, the risk of particulate contamination in infusion solutions during treatment is often underestimated.</p><p><strong>Methods: </strong>Residual amounts of infusion solutions prepared and administered at the adult intensive care unit were examined for visible and subvisible particles according to the recommendations of the European Pharmacopoeia monographs 2.9.19 and 2.9.20.</p><p><strong>Results: </strong>Samples from 169 infusion solutions were collected, 149 of which could be analysed. The Pharmacopoeia requirements for visible particles were not fulfilled in 42.9% (n=64/149) of the samples, while the requirements for subvisible particles were not met in 4.7% (n=7/149). A specific correlation between the pharmaceutical drugs or within the infusion set (bottle vs connected infusion line) and particulate contamination was not possible as the sample was too small for a correlation analysis. A Spearman rho analysis showed no correlation between particle contamination and administration mode (subvisible (10 µm): p=0.969, r=-0.005; subvisible (25 µm): p=0.834, r=-0.026; visible: p=0.711, r=-0.047) and particle contamination and dosage form (subvisible (10 µm): p=0.291, r=-0.092; subvisible (25 µm): p=0.513, r=0.057; visible: p=0.415, r=0.071).</p><p><strong>Conclusions: </strong>This study showed that residuals of intravenously administered solutions have particulate contaminations. A specific causal factor was not identified.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medication adherence in chronic myeloid leukemia: a hospital pharmacy-level analysis.","authors":"Violeta Getova-Kolarova, Maria Kamusheva, Natalia Kokudeva, Miglena Doneva, Ilko Getov","doi":"10.1136/ejhpharm-2025-004552","DOIUrl":"https://doi.org/10.1136/ejhpharm-2025-004552","url":null,"abstract":"<p><strong>Objectives: </strong>The objective was to evaluate medication adherence levels in patients with chronic myeloid leukaemia (CML) and to identify factors that may undermine adherence.</p><p><strong>Methods: </strong>This prospective, cross-sectional study was conducted over a 2-month period among ambulatory patients with CML monitored at one of the country's leading hospitals for diagnosing, treating and monitoring CML in Bulgaria.</p><p><strong>Results: </strong>Among 70 participants, 91.4% showed high medication adherence, with only 1.4% reporting low adherence. No significant differences in adherence between therapy groups (imatinib vs nilotinib, p=0.1830), gender (p=0.0887) or age groups (p=0.8748) were revealed. Education level was associated with adherence, with lower adherence observed in patients with primary education (p<0.0001). Quality of life, measured using utility values (median=0.8770) and visual analogue scale (mean=80), did not significantly differ based on adherence levels, therapy type or education level. Logistic regression showed that men had 1.9 times higher odds of high adherence compared with women (p>0.05). Patients under 65 had 3.3 times higher odds of adherence compared with those over 65 (p>0.05), and those on imatinib had 22.86% of the adherence odds compared with those on nilotinib. The findings suggest that maintaining high medication adherence is crucial for positive therapeutic outcomes in patients with CML.</p><p><strong>Conclusion: </strong>Patients with CML in Bulgaria show high medication adherence, likely contributing to their overall quality of life. These findings emphasise the importance of maintaining adherence for optimal treatment outcomes in CML. Future research should explore the factors influencing adherence in this population and assess the role of hospital pharmacists in supporting medication management.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}